Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Immuron Limited ( (AU:IMC) ) is now available.
Immuron Limited announced a change in the director’s interest, with Dr. Jeannette Joughin acquiring an additional 1,000,000 unlisted options, bringing her total to 2,000,000. This change was approved by shareholders at the company’s Annual General Meeting, indicating a strategic alignment with the company’s growth objectives and potentially impacting its market positioning.
More about Immuron Limited
Immuron Limited operates in the biotechnology industry, focusing on the development and commercialization of oral immunotherapeutics for the treatment of gut-mediated diseases. The company’s primary products are designed to target and modulate the immune system, offering potential treatments for a range of conditions.
Average Trading Volume: 538,302
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$17.23M
For an in-depth examination of IMC stock, go to TipRanks’ Overview page.